Streetbeat News

DNA

Ginkgo Bioworks Holdings, Inc.

https://www.ginkgobioworks.com

Industry

Biotechnology

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Open

10.28

Mkt cap

562M

Volume

1.5M

High

10.48

P/E Ratio

-0.73

52-wk high

75.20

Low

9.26

Div yield

N/A

52-wk low

5.26

Ferrari has announced a multi-year agreement to supply engines and gearboxes to a new Cadillac Formula One team starting in 2026. CEO Benedetto Vigna emphasized that Formula One is integral to Ferrari's identity.

Portfolio Pulse from

December 10, 2024 | 8:30 pm

Ginkgo Bioworks reported solid Q3 results, but the underlying performance was weaker due to non-cash revenue. The company is transitioning to a new business model focusing on upfront value creation and customer acquisition solutions. The success of this transition remains uncertain.

Portfolio Pulse from

November 18, 2024 | 4:00 pm

Ginkgo Bioworks reported mixed Q3 results, with a $45 million one-time revenue boost masking underlying revenue growth issues. Despite cost-cutting efforts, the company continues to report large losses and burned $325 million in cash in the first nine months of 2023. The balance sheet is weakening, and long-term revenue estimates have been lowered.

Portfolio Pulse from

November 13, 2024 | 2:00 pm

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) held its Q3 2024 earnings call on November 12, 2024. Key participants included CEO Jason Kelly and CFO Mark Dmytruk, with analysts from Morgan Stanley, Goldman Sachs, Bank of America, BTIG, and TD Cowen attending.

Portfolio Pulse from

November 13, 2024 | 3:15 am

Ginkgo Bioworks Holdings, Inc. (DNA) reported a Q3 loss of $1.08 per share, which was better than the Zacks Consensus Estimate of a $2.40 loss. This is an improvement from the $3.60 loss per share reported a year ago.

Portfolio Pulse from

November 13, 2024 | 1:15 am

23andMe, a DNA-testing company, is undergoing significant restructuring, including laying off 200 employees (40% of its workforce) and discontinuing its therapeutic programs.

Portfolio Pulse from

November 12, 2024 | 10:15 pm

Ginkgo Bioworks announced its Q3 2024 financial results, highlighting restructuring efforts, site consolidation, and cost reductions. The company also reported new and expanded deals with Novo Nordisk and a research milestone with Merck.

Portfolio Pulse from

November 12, 2024 | 10:15 pm

Ginkgo Bioworks has achieved the first milestone in its partnership with Merck to enhance biologics manufacturing, resulting in a $9 million research milestone payment.

Portfolio Pulse from

November 12, 2024 | 1:15 pm

Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) will present its Q3 2024 results on November 12, 2024, post-market. The presentation will include a Q&A session and will be accessible via their investor relations website.

Portfolio Pulse from

November 05, 2024 | 12:30 pm

Ginkgo Bioworks Holdings, Inc. (DNA) experienced a decline of 1.55% in its stock price, closing at $7.63, which was a larger drop compared to the broader market.

Portfolio Pulse from

November 05, 2024 | 12:30 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.